Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus ULTRATAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus ULTRATAG.
INDIUM IN 111 OXYQUINOLINE vs ULTRATAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 oxyquinoline is a radiolabeled compound that chelates indium-111 with oxyquinoline. The lipophilic complex penetrates cell membranes and binds to intracellular components, primarily in leukocytes (neutrophils). After intravenous injection, the radiolabeled cells accumulate at sites of inflammation or infection, allowing gamma camera imaging to detect focal areas of abnormal leukocyte localization.
Inhibits hepatic glucose production by activating AMP-activated protein kinase (AMPK) and reduces intestinal glucose absorption; also improves insulin sensitivity.
1-2 mCi (37-74 MBq) labeled autologous leukocytes, administered intravenously over 1-2 minutes.
NOT FOUND
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours for the free indium ion, but biological half-life for labeled cells can be 1-2 days depending on cell type.
Terminal elimination half-life is 12-15 hours (mean 13.5 h); clinically significant for twice-daily dosing in hepatic impairment or drug interactions.
Renal excretion approximately 70-80% within 24 hours; fecal excretion less than 5%.
Primarily renal excretion of unchanged drug (60-70%); biliary excretion accounts for 20-25%; fecal elimination <10%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical